阿伐曲泊帕治疗肝硬化和原发性肝癌患者血小板减少症疗效分析*

doi:10.3969/j.issn.1672-5069.2023.03.035

Abstract

Zhong Huan, Ye Wei. Very short-term observation of avatrombopag for the treatment of patients with liver cirrhosis and primary liver cancer and thrombocytopenia[J]. Journal of Practical Hepatology, 2023, 26(3): 440-442.

References

[1] Peck-Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int, 2017, 37(6): 778-793.
[2] Temel T, Cansu DU, Temel HE, et al. Serum thrombopoietin levels and its relationship with thrombocytopenia in patients with cirrhosis. Hepat Mon, 2014, 14(5): e18556.
[3] Terrault N, Chen YC, Izumi N, et al. Avatrombopag before procedures reduces need for platelet transfusion in patients with chronic liver disease and thrombocytopenia. Gastroenterology, 2018, 155(3): 705-718.
[4] 中华医学会肝病学分会,肝硬化诊治指南.临床肝胆病杂志,2019,35(11):2408-2425.
[5] 中华人民共和国国家卫生健康委员会医政医管局,中华肝脏病杂志,2022,30(4): 367-388.
[6] Saab S, Brown RS. Management of thrombocytopenia in patients with chronic liver disease. Dig Dis Sci, 2019, 64(10): 2757-2768.
[7] Kuter DJ. The structure, function, and clinical use of the thrombopoietin receptor agonist avatrombopag. Blood Rev, 2022, 53: 100909.
[8] Eguchi Y, Takahashi H, Mappa S, et al. Phase 2 study of avatrombopag in Japanese patients with chronic liver disease and thrombocytopenia. Hepatol Res, 2022, 52(4): 371-380.
[9] Lu J, Jamieson BD, Hui AM. Avatrombopag ethnic sensitivity analysis in chronic liver disease and thrombocytopenia patients: individual-level pooled analysis. Therap Adv Gastroenterol, 2022, 15: 17562848221105976.
[10] 蒋孝华, 谢玉桃, 谭德明. 病毒性肝炎血小板减少症影响因素的研究. 中华肝脏病杂志, 2004(12): 36-38.
[11] Djordjević J, Svorcan P, Vrinić D, et al. Splenomegaly and thrombocytopenia in patients with liver cirrhosis. Vojnosanit Pregl, 2010, 67(2): 166-169.
[12] Dahal S, Upadhyay S, Banjade R, et al. Thrombocytopenia in patients with chronic hepatitis C virus infection. Mediterr J Hematol Infect Dis, 2017, 9(1): e2017019.
[13] Tejima K, Masuzaki R, Ikeda H, et al. Thrombocytopenia is more severe in patients with advanced chronic hepatitis C than B with the same grade of liver stiffness and splenomegaly. J Gastroenterol, 2010, 45(8): 876-884.
[14] European Association for the Study of the Liver, Electronic address: easloffice@easloffice.eu, european association for the study of the liver. EASL Clinical Practice Guidelines on prevention and management of bleeding and thrombosis in patients with cirrhosis. J Hepatol, 2022, 76(5): 1151-1184.
[15] 中华医学会器官移植学分会围手术期管理学组. 成人肝移植受者围术期凝血功能管理专家共识(2021年版). 实用器官移植电子杂志, 2021,9(2):89-94.
[16] 王永帅, 张赛, 李磊等. 阿伐曲泊帕联合重组人血小板生成素和阿伐曲泊帕单药治疗慢性肝病相关重度血小板减少症的临床疗效. 中华消化外科杂志, 2022, 21(2): 281-286.
[17] Scharf RE. Thrombocytopenia and hemostatic changes in acute and chronic liver disease: pathophysiology, clinical and laboratory features, and management. J Clin Med, 2021, 10(7): 1530.

Very short-term observation of avatrombopag for the treatment of patients with liver cirrhosis and primary liver cancer and thrombocytopenia

PDF (PC)

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments

[1]	Zhang Shaoquan, Lin Bingliang. Gut microbiota in patients with liver cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(3): 313-316.
[2]	Zhang Danlei, Xu Jing. Early antiviral efficacy of tenofovir amibufenamide in treatment of naïve patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 336-339.
[3]	Guo Xiaoling, Zhang Yaowu, Li Mengtao, et al.. Auxiliary treatment of a herbal compound, Ganshuang granule, with entecavir for patients with chronic hepatitis B [J]. Journal of Practical Hepatology, 2023, 26(3): 340-343.
[4]	Wang Yunyun, Wu Wanfeng, Li Li. Antiviral efficacy and impact on blood glucose control of direct acting antivirals in treatment of patients with genotype 1b chronic hepatitis C and type 2 diabetes mellitus [J]. Journal of Practical Hepatology, 2023, 26(3): 344-347.
[5]	Xu Haimiao, Zheng Ruiqi, Ding Huiguo. Short-term efficacy of pitavastatin and polyene phosphatidyl choline combination in the treatment of patients with nonalcoholic steatohepatitis [J]. Journal of Practical Hepatology, 2023, 26(3): 352-355.
[6]	Guo Yinyan, Yue Zhi, Gai Xiaodong, et al.. Clinical and liver pathological features of patients with autoimmune hepatitis- primary biliary cholangitis overlap syndrome [J]. Journal of Practical Hepatology, 2023, 26(3): 372-375.
[7]	Wang Junhong, Dai Ling, Chen Guobin, et al.. Cost-effectiveness analysis of reduced glutathione,diammonium glycyrrhizinate and glycyrrhizin in the treatment of patients with anti-tuberculosis medicine-induced liver injury [J]. Journal of Practical Hepatology, 2023, 26(3): 380-383.
[8]	Wei Dongping, Han Lili, Ling Jiahui, et al.. Efficacy of glycyrrhizic acid diamine and compound glycyrrhizin in the treatment of patients with cyclophosphamide-induced liver injury [J]. Journal of Practical Hepatology, 2023, 26(3): 388-391.
[9]	Ye Sitao, Huang Xiaoquan, Chen Shiyao. Plasma fibrinogen level predicts gastroesophageal variceal rebleeding in patients with hepatitis B-induced liver cirrhosis after endoscopic treatment [J]. Journal of Practical Hepatology, 2023, 26(3): 392-395.
[10]	Liu Kun, Xu Jing, Ma Zhufang. Transient improvement of patients with liver cirrhosis-induced refractory ascites by oral tolvaptan administration at base of concentrated ascites reinfusion [J]. Journal of Practical Hepatology, 2023, 26(3): 396-399.
[11]	Liu Lingyu, Wang Wei, Tang Jiamei. Application of ultrasound three-dimensional speckle tracking imaging in the early diagnosis of cirrhotic cardiomyopathy in patients with decompensated cirrhosis [J]. Journal of Practical Hepatology, 2023, 26(3): 400-403.
[12]	Shi Lei, An Ziming, Feng Qin. Clinical implication of serum AFP, AFP-L3% and PIVKA-II in early diagnosing and predicting prognosis of patients with primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(3): 404-407.
[13]	Chen Qiquan, Li Xiaoting, Yang Xunyi, et al.. Diagnostic efficacy of liver contrast-enhanced ultrasound, shear wave elastography and contrast-enhanced CT scan in patients with occupying lesions in liver [J]. Journal of Practical Hepatology, 2023, 26(3): 408-411.
[14]	Lin Yongzhu, Shi Hongyuan, Mu Xihu. Diagnosis of small primary liver cancer under the background of liver cirrhosis by dual-source CT hepatic artery three-phase scanning and enhanced perfusion scanning [J]. Journal of Practical Hepatology, 2023, 26(3): 412-415.
[15]	Tang Liang, Chen Xi, Wang Wengao. Short-term clinical efficacy of TACE and 3D-CRT in the treatment of patients with advanced primary liver cancer [J]. Journal of Practical Hepatology, 2023, 26(3): 416-419.